Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration

Main Article Content

Benjamin Ehst
Oregon Medical Research Center, Portland, OR

George Han
Icahn School of Medicine at Mount Sinai, New York, NY

Scott Guenthner
The Dermatology Center of Indiana, Plainfield, IN

Kimberly Eads
The Indiana Clinical Trials Center, PC, Plainfield, IN

Abby Jacobson
Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ

Keywords

psoriasis, brodalumab

Abstract

Abstract not available.

References

1. Siliq [package insert]. Valeant Pharmaceuticals North America LLC; 2017.

2. Lebwohl et al. N Engl J Med. 2015;373:1318-1328.

Article Sidebar

Poster PDF
Published
2019-11-09
DOI: https://doi.org/10.25251/skin.3.supp.25

Article Details

How to Cite
[1]
2019. Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration . SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S25. DOI:https://doi.org/10.25251/skin.3.supp.25.
Issue
Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 > >>